Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? - Bilgir, O.; Kebapcilar, L.; Bilgir, F.; Sarì, I.; Oner, P.; Karaca, B.; Alacacioglu, I. (International journal of clinical practice (Esher), 2010)
Keywords: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents - adverse effects; Benzamides; Cosyntropin; Endocrine System Diseases - chemically induced; Endocrine System Diseases - metabolism; Endocrinology; Female; Glucagon; Glucocorticoids - deficiency; Hormones; Humans; Hydrocortisone - metabolism; Hypothalamo-Hypophyseal System - drug effects; Imatinib Mesylate; Inhibitor drugs; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Male; Middle Aged; Pharmacology; Piperazines - adverse effects; Pituitary-Adrenal System - drug effects; Protein Kinase Inhibitors - adverse effects; Pyrimidines - adverse effects